Form 4 for CCCC C4 Therapeutics, Inc.
Accepted 2021-12-23 00:00:00 ET · period of report 2021-12-22 · accession 0001209191-21-071069 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-23 | 2021-12-22 | CCCC | Crystal Adam | Chief Medical Off | M - OptEx | $6.49 | +5,000 | 15.0K | +50% | +$32.5K |
| D | 2021-12-23 | 2021-12-22 | CCCC | Crystal Adam | Chief Medical Off | M - OptEx | $0.00 | -5,000 | 127.3K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-22 | M | A | 5,000 | $6.49 | 15,000 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2021-12-22 | M | D | 5,000 | $0.00 | 127,292 | D | $6.49 · — to 2029-04-08 | 5,000 Common Stock | (F1) 25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter. |